Cerebrolysin
Also known as: FPF-1070, Neuropeptide preparation, Porcine brain neuropeptides
Overview
Cerebrolysin is a lipid-free neuropeptide preparation produced by standardized enzymatic breakdown of purified porcine brain proteins. The resulting mixture of low-molecular-weight neuropeptides and free amino acids (all below 10 kDa) can cross the blood-brain barrier and interact directly with neurons, unlike most endogenous neurotrophic factors. With data from more than 200 clinical trials involving approximately 15,000 patients, it has one of the most extensive clinical databases of any nootropic peptide preparation, including studies in stroke, TBI, Alzheimer's disease, and vascular dementia.
Mechanism of Action
Cerebrolysin simultaneously activates multiple neuroprotective mechanisms: stimulating production of endogenous neurotrophic factors (BDNF, GDNF, NGF, CNTF) via direct peptide supply and upregulation of their synthesis; reducing excitotoxicity by modulating excessive glutamate activity; inhibiting apoptosis and reducing neurofibrillary tangle formation; promoting neurogenesis and synaptogenesis in the hippocampus; modifying NTF and Sonic Hedgehog signaling pathways governing myelination and neurovascular integrity; and activating CREB/PGC-1-alpha to suppress neuroinflammatory cytokines.
Potential Benefits
- Most extensively studied nootropic peptide preparation with >200 clinical trials
- Improved post-stroke functional independence (CARS trial)
- Reduced infarct volume and brain edema in TBI models
- Cognitive improvements in Alzheimer's disease (multiple RCTs with ADAS-cog improvements)
- Motor function improvements in stroke rehabilitation
- Supports neurogenesis and synaptic density in hippocampus
- Direct neurotrophic factor activity bypassing blood-brain barrier limitations
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Typical Range | 5-30 ml/day IV (clinical); 5-10 ml/day IM (research) |
| Beginner | 5 ml/day IM for 10 days |
| Intermediate | 10 ml/day IM or IV for 10-20 days |
| Advanced | 20-30 ml/day IV for 20-28 days (clinical stroke protocol) |
| Cycle Duration | 10-28 day courses |
| Cycle Off | 4-8 weeks between courses |
Cerebrolysin is a neuropeptide complex (not a single peptide) containing multiple neurotrophic peptide fragments. Clinical trials used 10-30 ml/day IV. IM dosing at 5-10 ml is practical for outpatient research protocols. Courses of 10-28 days are standard, followed by rest periods.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Intramuscular Injection High
Practical research and off-label route; 5-10 ml per injection; approved IM route in many countries
Subcutaneous Injection High
Alternative to IM; used in some research protocols; volume limitations may restrict dose per injection
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving Cerebrolysin:
Neurological Recovery Stack
Comprehensive neuroprotection and neurorehabilitation
Cerebrolysin provides neurotrophic factor complex; Semax raises BDNF; Epithalon adds anti-aging and neuroendocrine support. Used in Eastern European post-stroke protocols.
Cognitive Enhancement Stack
Neurotrophic support, synaptogenesis, and neuronal energy restoration
Cerebrolysin provides the neurotrophic complex; Dihexa drives new synaptic connections; NAD+ supports mitochondrial function in neurons.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Typical Vial Size | 5ml/vial, 10ml/vial, 20ml/vial |
|---|---|
| BAC Water | N/A — supplied as ready-to-use solution; dilute in saline for IV infusion |
| Storage | Refrigerate at 2-8°C; do not freeze; protect from light |
| Shelf Life | 36 months unopened; use immediately once ampule opened |
Need exact syringe measurements?
Amino Acid Sequence
Complex mixture; individual component peptides are small fragments of porcine brain proteins, each <10 kDa
Side Effects & Safety
- Generally well-tolerated with IV/IM administration
- Mild nausea or dizziness at high doses
- Rare allergic reactions
- Injection site reactions
- Seizure threshold lowering (rare, theoretical)
Synergistic Compounds
The following compounds have been studied alongside Cerebrolysin for potential complementary or synergistic effects:
Learn More
References & Further Reading
- [object Object]
- [object Object]